Coherus Ranibizumab Sales Quadruple Thanks To Q-Code Boost

Firm Also Looking At More Adalimumab PBM, Distribution Deals

Coherus BioSciences has welcomed an uplift of sales for its ranibizumab biosimilar, as well as discussing its efforts to reinvigorate its pegfilgrastim biosimilar franchise, during the company’s second-quarter earnings call.

Eye
• Source: Shutterstock

Successfully implementing the product-specific Q-code for the company’s Cimerli (ranibizumab-eqrn) biosimilar to Genentech’s Lucentis from 1 April saw sales of Coherus BioSciences’ product more than quadruple in the second quarter, from $6.2m to $26.7m, realizing an anticipated uptick for the company.

Meanwhile, Cimerli’s market share amongst the ranibizumab products in the market also more than quadrupled from 4.1% to 17% in...

More from Biosimilars

More from Products